

Revision date: 18-Jul-2014

Version: 4.0

Pfizer Ltd

**CT13 9NJ** 

**Ramsgate Road** 

Sandwich, Kent

United Kingdom +00 44 (0)1304 616161

**Emergency telephone number:** 

International CHEMTREC (24 hours): +1-703-527-3887

Page 1 of 8

# 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING Product Identifier

Material Name: Fluconazole Solution for Infusion, IV

| Trade Name:      | DIFLUCAN®, FUNGUSTATIN; TRIFLUCAN; ZOLTEC           |
|------------------|---|
| Chemical Family: | Synthetic class of compounds known as bis-triazoles |

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Intended Use: Pharmaceutical product used as antifungal agent

Details of the Supplier of the Safety Data Sheet Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com

# 2. HAZARDS IDENTIFICATION

| Classification of the Substance or Mixture |                             |  |  |
|--|-----------------------------|--|--|
| GHS - Classification                       | Not classified as hazardous |  |  |

**EU Classification:** 

EU Indication of danger: Not classified

Label Elements

| Other Hazards<br>Australian Hazard Classification<br>(NOHSC): | No data available<br>Non-Hazardous Substance. Non-Dangerous Goods.  |
|---|---|
| Note:   | This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace. |
| Additional Information:                                       | For a more detailed discussion of potential health hazards and toxicity see Section 11.   |

# Material Name: Fluconazole Solution for Infusion, IV Revision date: 18-Jul-2014

# 3. COMPOSITION / INFORMATION ON INGREDIENTS

#### Hazardous

| Ingredient      | CAS Number | EU<br>EINECS/ELINCS<br>List | EU Classification                         | GHS<br>Classification  | %   |
|-----------------|------------|-----------------------------|---|--|-----|
| Sodium chloride | 7647-14-5  | 231-598-3                   | Not Listed                                | Not Listed   | *   |
| Fluconazole     | 86386-73-4 | Not Listed                  | Xn;R22<br>Repr.Cat.2;R61<br>R64<br>R52/53 | Acute Tox. 4(H302)<br>Repr. 1B (H360D)<br>Lact. (H362)<br>Aquatic Acute 3<br>(H402)<br>Aquatic Chronic 3<br>(H412) | 0.2 |

| Ingredient            | CAS Number | EU<br>EINECS/ELINCS<br>List | EU Classification | GHS<br>Classification | % |
|-----------------------|------------|-----------------------------|-------------------|-----------------------|---|
| Dextrose, monohydrate | 5996-10-1  | Not Listed                  | Not Listed        | Not Listed            | * |

#### **Additional Information:**

\* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

been withheld as a trade secret.

| 4. FIRST AID MEASURES                             |   |
|---|---|
|   |   |
| Description of First Aid Measures<br>Eve Contact: | Flush with water while holding evelids open for at least 15 minutes. Seek medical attention |

|                                     | immediately.   |
|-------------------------------------|--|
| Skin Contact:                       | Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.  |
| Ingestion:                          | Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately. |
| Inhalation:                         | Remove to fresh air and keep patient at rest. Seek medical attention immediately.  |
| Most Important Symptoms and Effect  | ts, Both Acute and Delayed   |
| Symptoms and Effects of             | For information on potential signs and symptoms of exposure, See Section 2 - Hazards   |
| Medical Conditions                  | None known   |
| Aggravated by Exposure:             |  |
| Indication of the Immediate Medical | Attention and Special Treatment Needed   |
| Notes to Physician:                 | None   |

# **5. FIRE FIGHTING MEASURES**

**Extinguishing Media:** 

Use carbon dioxide, dry chemical, or water spray.

# Material Name: Fluconazole Solution for Infusion, IV Revision date: 18-Jul-2014

#### Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Carbon monoxide, carbon dioxide, nitrogen oxides and fluorine-containing compounds Products:

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

#### **Advice for Fire-Fighters**

Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight fire from a safe distance.

# 6. ACCIDENTAL RELEASE MEASURES

#### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Methods and Material for Containment and Cleaning Up

| Measures for Cleaning /<br>Collecting:        | Use non-combustible absorbent material to wipe up spill and place in a sealed container for disposal. Clean spill area thoroughly.   |
|---|--|
| Additional Consideration for<br>Large Spills: | Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel. |

#### 7. HANDLING AND STORAGE

#### Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

#### Conditions for Safe Storage, Including any Incompatibilities

| Storage Conditions:  | Store as directed by product packaging. |
|----------------------|---|
| Specific end use(s): | Pharmaceutical drug product             |

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### **Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

| Sodium chloride<br>Latvia OEL - TWA<br>Lithuania OEL - TWA | 5 mg/m <sup>3</sup><br>5 mg/m <sup>3</sup>   |
|--|--|
| Fluconazole<br>Pfizer OEL TWA-8 Hr:                        | 500µg/m³   |
| Analytical Method:<br>Exposure Controls                    | Analytical method available for Fluconazole. Contact Pfizer Inc for further information.   |
| Engineering Controls:                                      | Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. |

Material Name: Fluconazole Solution for Infusion, IV Revision date: 18-Jul-2014

#### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION **Personal Protective** Refer to applicable national standards and regulations in the selection and use of personal Equipment: protective equipment (PPE). Impervious gloves are recommended if skin contact with drug product is possible and for bulk Hands: processing operations. Eyes: Wear safety glasses or goggles if eye contact is possible. Impervious protective clothing is recommended if skin contact with drug product is possible and Skin: for bulk processing operations. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate **Respiratory protection:** respirator with a protection factor sufficient to control exposures to below the OEL.

# 9. PHYSICAL AND CHEMICAL PROPERTIES

| Physical State:   | Liquid  | Color:  | hrochold.    | Colorless |
|---|---|---|--------------|-----------|
| Odor:<br>Molecular Formula:   | Mixture   | Molecu  | ilar Weight: | Mixture   |
| Solvent Solubility:<br>Water Solubility:  | No data available                               |   |              |           |
| pH:   | 4 - 8; 3.5 - 6.5<br>(sodium chloride solution): | (dextrose solution)   |              |           |
| Melting/Freezing Point (°C):<br>Boiling Point (°C):   | No data available<br>No data available.         | (,  |              |           |
| Partition Coefficient: (Method, pH, Er<br>Sodium chloride   | ndpoint, Value)                                 |   |              |           |
| No data available   |   |   |              |           |
| Predicted Log P 5.0   |   |   |              |           |
| Dextrose monohydrate  |   |   |              |           |
| No data available   |   |   |              |           |
| Decomposition Temperature (°C):   | No data available.                              |   |              |           |
| Evaporation Rate (Gram/s):  | No data available                               |   |              |           |
| Vapor Pressure (kPa):   | No data available                               |   |              |           |
| Vapor Density (g/ml):   | No data available                               |   |              |           |
| Relative Density:   | No data available                               |   |              |           |
| Viscosity:  | No data available                               |   |              |           |
| Flammablity:  |   |   |              |           |
| Autoignition Temperature (Sol<br>Flammability (Solids):<br>Flash Point (Liquid) (°C):<br>Upper Explosive Limits (Liquid<br>Lower Explosive Limits (Liquid | id) (°C):<br>d) (% by Vol.):<br>d) (% by Vol.): | No data available<br>No data available<br>No data available<br>No data available<br>No data available |              |           |
| r orymenzation.   |   |   |              |           |

# **10. STABILITY AND REACTIVITY**

Reactivity: Chemical Stability: Possibility of Hazardous Reactions Oxidizing Properties: Conditions to Avoid: No data available Stable under normal conditions of use.

No data available Protect from freezing

# Material Name: Fluconazole Solution for Infusion, IV Revision date: 18-Jul-2014

#### **10. STABILITY AND REACTIVITY**

Incompatible Materials: As a pre Hazardous Decomposition No data Products:

As a precautionary measure, keep away from strong oxidizers No data available

# 11. TOXICOLOGICAL INFORMATION

| Information on Toxicological Effects |  |
|--------------------------------------|--|
| General Information:                 | The information included in this section describes the potential hazards of the individual ingredients.  |
| Short Term:                          | May cause irritation (based on components).  |
| Long Term:                           | Repeat-dose studies in animals have shown a potential to cause adverse effects on liver. and the developing fetus.   |
| Known Clinical Effects:              | Clinical use of this drug has caused headache, skin rash, vomiting, abdominal pain, and diarrhea. Fluconazole is found in human breast milk at concentrations similar to plasma. Therefore, nursing mothers should limit exposure. There have been reports of multiple congenital abnormalities in infants whose mothers were being treated for 3 or more months with high dose (400-800mg/day) fluconazole. Rare cases of serious liver damage and allergic reactions have been reported. |

#### Acute Toxicity: (Species, Route, End Point, Dose)

#### Sodium chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD50 4000 mg/kg

#### Fluconazole

Rat (F) Oral LD50 1575 mg/kg Rat (M) Oral LD50 1325mg/kg Mouse Oral LD50 1410mg/kg Mouse (M) Oral LD50 1520mg/kg Intravenous LD50 > 100mg/kg Dog A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable **Acute Toxicity Comments:** at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

#### Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Fluconazole

| 3 Month(s)  | Rat | Oral5 mg/kg/day    | NOAEL L | iver  |
|-------------|-----|--------------------|---------|-------|
| 6 Month(s)  | Dog | Oral 7.5 mg/kg/day | NOAEL   | Liver |
| 12 Month(s) | Rat | Oral 10 mg/kg/day  | LOAEL   | Liver |
| 12 Month(s) | Dog | Oral 2.5 mg/kg/da  | y NOAEL | Liver |

# Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Fluconazole

# Material Name: Fluconazole Solution for Infusion, IV Revision date: 18-Jul-2014

# 11. TOXICOLOGICAL INFORMATION

Reproductive & Fertility Rat Oral20 mg/kg/day NOAEL Negative Embryo / Fetal Development Rabbit Oral 20 mg/kg/day NOAEL Maternal Toxicity, Not Teratogenic Embryo / Fetal Development Rat Oral 5 mg/kg/day NOAEL Fetotoxicity, Maternal Toxicity Embryo / Fetal Development Rat Oral 80 mg/kg/day LOAEL Maternal Toxicity, Developmental toxicity

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

#### Fluconazole

In Vitro Bacterial Mutagenicity (Ames)Salmonella , E. coliNegativeIn Vivo CytogeneticsMouse Bone MarrowNegativeIn Vitro CytogeneticsHuman LymphocytesNegative

#### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Fluconazole

24 Month(s)Rat FemaleOral 10 mg/kg/dayNOAELNot carcinogenic24 Month(s)Rat FemaleOral 5 mg/kg/dayLOELBenign tumors, Liver24 Month(s)MouseOral 10 mg/kg/dayNOELNot carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

# **12. ECOLOGICAL INFORMATION**

**Environmental Overview:** The environmental characteristics of this mixture have not been fully evaluated. Based on the concentration of the active ingredient in the formulation, No harmful effects to aquatic organisms are expected.

Toxicity:

#### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

# FluconazoleDaphnia magna (Water Flea)LC5048 Hours 35 mg/LPimephales promelas (Fathead Minnow)LC50> 50 mg/LCyprinodon variegatus (Sheepshead Minnow)LC50> 50 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: Partition Coefficient: (Method, pH, Endpoint, Value) Fluconazole Predicted Log P 5.0

Mobility in Soil: No data available

Material Name: Fluconazole Solution for Infusion, IV Revision date: 18-Jul-2014

Page 7 of 8 Version: 4.0

## **13. DISPOSAL CONSIDERATIONS**

Waste Treatment Methods:Dispose of waste in accordance with all applicable laws and regulations. Member State<br/>specific and Community specific provisions must be considered. Considering the relevant<br/>known environmental and human health hazards of the material, review and implement<br/>appropriate technical and procedural waste water and waste disposal measures to prevent<br/>occupational exposure and environmental release. It is recommended that waste minimization<br/>be practiced. The best available technology should be utilized to prevent environmental<br/>releases. This may include destructive techniques for waste and wastewater.

# **14. TRANSPORT INFORMATION**

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# **15. REGULATORY INFORMATION**

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications WHMIS hazard class: Class D, Division 2, Subdivision A



| Dextrose, monohydrate                       |            |
|---|------------|
| CERCLA/SARA 313 Emission reporting          | Not Listed |
| California Proposition 65                   | Not Listed |
| EU EINECS/ELINCS List                       | Not Listed |
| Sodium chloride                             |            |
| CERCLA/SARA 313 Emission reporting          | Not Listed |
| California Proposition 65                   | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present    |
| Australia (AICS):                           | Present    |
| EU EINECS/ELINCS List                       | 231-598-3  |
| Fluconazole                                 |            |
| CERCLA/SARA 313 Emission reporting          | Not Listed |
| California Proposition 65                   | Not Listed |
| Standard for the Uniform Scheduling         | Schedule 3 |
| for Drugs and Poisons:                      | Schedule 4 |
| EU EINECS/ELINCS List                       | Not Listed |
|   |            |

Material Name: Fluconazole Solution for Infusion, IV Revision date: 18-Jul-2014

# **16. OTHER INFORMATION**

# Text of R phrases and GHS Classification abbreviations mentioned in Section 3

| Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed<br>Reproductive toxicity-Cat.1B; H360D - May damage the unborn child<br>Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children<br>Hazardous to the aquatic environment, acute toxicity-Cat.3; H402 - Harmful to aquatic life<br>Hazardous to the aquatic environment, chronic toxicity-Cat.3; H412 - Harmful to aquatic life with long lasting effects |  |  |  |
|--|--|--|--|
| Xn - Harmful<br>Toxic to Reproduction: Category 2  |  |  |  |
| R22 - Harmful if swallowed.<br>R61 - May cause harm to the unborn ch<br>R64 - May cause harm to breastfed bab<br>R52/53 - Harmful to aquatic organisms,  | ild.<br>ies.<br>may cause long-term adverse effects in the aquatic environment.  |  |  |
| Data Sources:  | Pfizer proprietary drug development information. Publicly available toxicity information. Safety data sheets for individual ingredients. |  |  |
| Reasons for Revision:  | Updated Section 7 - Handling and Storage.  |  |  |
| Revision date:   | 18-Jul-2014  |  |  |
| Prepared by:   | Pfizer Global Environment, Health, and Safety Operations   |  |  |

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet